Android app on Google Play

UPDATE: Dendreon Corp. (DNDN) Rated Buy at R.F. Lafferty

September 9, 2013 11:20 AM EDT Send to a Friend
Get Alerts DNDN Hot Sheet
Price: $1.50 +5.63%

Rating Summary:
    3 Buy, 18 Hold, 12 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 24 | New: 21
Trade DNDN Now!
Join SI Premium – FREE
(Updated - September 9, 2013 12:49 PM EDT)

Dendreon Corp. (Nasdaq: DNDN) was rated new Buy by R.F. Lafferty with a price target of $8. Lafferty noted low expectations for Provenge, a drug analysts have strong conviction will have a place in treatment of prostate cancer. Lafferty thinks the company is positioned to turn profitable. Against this backdrop, analysts view risk/reward as positive.

For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.

Shares of Dendreon closed at $2.88 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Add Your Comment